Systemic sclerosis (scleroderma) trials in Japan

In Japan 5 Also abroad 213

5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Fukuoka, Kanazawa, Maebashi, Nagoya, Sapporo, Yokohama
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Aichi, Nagoya, Aichi, Toyoake, Fukuoka, Kitakyushu, Gifu, Gifu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Ishikawa, Kanazawa, Kagawa, Kita-gun, Kanagawa, Kawasaki, Kanagawa, Sagamihara, Kanagawa, Yokohama, Kyoto, Kyoto, Miyagi, Sendai, Nagasaki, Nagasaki, Osaka, Takatsuki, Saitama, Iruma-gun, Tokyo, Bunkyo-ku, Tokyo, Shinjuku-ku, Toyama, Toyama
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 3Not yet taking people in Japan
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Where
Bunkyo-ku, Fukuoka, Maebashi, Okayama, Sapporo, Suita, Yokohama
Age
16 years and over
People
92 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00
Phase 3Taking people
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Where
Aichi, Gunma, Hiroshima, Hokkaido, Tokushima, Tokyo, Yamanashi
Age
18 years and over
People
514 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06716606
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Gunma, Hiroshima, Hokkaido, Kanagawa, Miyagi, Shizuoka, Tokushima, Tokyo
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01